SFRP2 (Secreted Frizzled-Related Protein 2): Molecular Function, Wnt Signaling Modulation, Fibrosis, Angiogenesis, and Translational Biomarker Relevance

SFRP2 (Secreted Frizzled-Related Protein 2) is a secreted extracellular glycoprotein encoded by the SFRP2 gene and classified within the secreted frizzled-related protein (sFRP) family, a conserved group of soluble modulators of Wnt signaling pathways. According to the curated NCBI Gene entry for human SFRP2, the gene is located on chromosome 4q31.21 and encodes a protein characterized by a Frizzled-like cysteine-rich domain (CRD), structurally homologous to the Wnt-binding domain of Frizzled receptors.

Unlike intracellular Wnt pathway regulators, SFRP2 functions in the extracellular space, where it modulates ligand–receptor interactions, signaling gradients, and pathway bias. This extracellular mode of action underlies its repeated implication in developmental signaling, fibrotic tissue remodeling, angiogenesis, tumor microenvironment biology, and epigenetic biomarker discovery.

The primary human transcript of SFRP2 is annotated in RefSeq as NM_003013.3. The encoded protein contains two evolutionarily conserved regions:

1. An N-terminal cysteine-rich domain (CRD) homologous to Frizzled receptors
2. A C-terminal netrin-like (NTR) domain, conserved across sFRP family members

Domain-level annotation in the NCBI Conserved Domain Database (CDD) identifies the CRD of SFRP2 as structurally optimized for Wnt ligand interaction. The UCSC Genome Browser SFRP2 gene annotation (hg38) further confirms the presence of a signal peptide and extracellular localization, consistent with secretion into the interstitial space and extracellular matrix.

Because SFRP2 is secreted, its biological activity depends strongly on local concentration, matrix binding, and cell-type–specific receptor availability, rather than bulk tissue expression alone.

Beyond the Classical “Wnt Antagonist” Model

Early models described sFRPs as Wnt antagonists. However, experimental evidence demonstrates that SFRP2 acts as a Wnt signaling modulator, capable of either attenuating or enhancing pathway output depending on context. A mechanistic study available through PubMed Central demonstrated that SFRP2 can augment Wnt3a-induced signaling, promoting LRP6 phosphorylation, β-catenin stabilization, and canonical Wnt transcriptional activity.

This finding is consistent with the functional summary provided in the NCBI Gene description for SFRP2, which emphasizes pathway modulation rather than strict inhibition.

Endothelial Signaling and NFAT Activation

A pivotal advance in SFRP2 biology came from studies identifying it as a pro-angiogenic factor. Experimental work indexed in PubMed and available in full via PubMed Central demonstrated that SFRP2 stimulates endothelial cell migration and neovascularization through activation of the calcineurin–NFAT signaling axis.

Subsequent receptor-focused studies identified Frizzled-5 (FZD5) as a high-affinity receptor for SFRP2, as reported in a PubMed-indexed study on SFRP2–FZD5 signaling. These findings positioned SFRP2 at the intersection of noncanonical Wnt signaling and calcium-dependent transcriptional control.

Tumor Endothelium and Angiogenic Programs

A comprehensive synthesis of these findings is provided in the PubMed review on SFRP2 in tumor angiogenesis, which highlights SFRP2 enrichment in tumor-associated endothelial cells rather than malignant epithelial compartments. Age-dependent angiogenic signaling involving SFRP2 has also been described in a PubMed study on age-related tumor vascularization.

Cardiac Repair and Fibroblast Activation

SFRP2 has been extensively studied in cardiac injury and repair. A foundational paracrine signaling study available via PubMed Central identified SFRP2 as a key survival-promoting factor in myocardial injury models, linking it to Akt-dependent signaling.

Later work indexed in PubMed demonstrated that SFRP2 activates β-catenin–dependent transcription in cardiac fibroblasts, reinforcing its role as a context-specific regulator of mesenchymal Wnt signaling. The therapeutic implications of these findings were explored in a PubMed Central article on SFRP2 as an antifibrotic target.

Pulmonary Fibrosis and TGF-β Crosstalk

More recently, SFRP2 has been implicated in idiopathic pulmonary fibrosis (IPF). A Journal of Clinical Investigation study indexed in PubMed identified a fibroblast-dependent TGF-β1/SFRP2 noncanonical Wnt signaling axis that promotes pathological epithelial remodeling, placing SFRP2 at the center of intercellular fibrosis signaling networks.

DNA Methylation as a Noninvasive Biomarker

SFRP2 is one of the most extensively studied epigenetic biomarkers in colorectal cancer (CRC). Early work demonstrated that SFRP2 promoter hypermethylation can be detected in fecal DNA, as reported in a PubMed study on fecal DNA methylation and validated in full-text form via PubMed Central.

Subsequent panel-based methylation analyses incorporating SFRP2 were described in PubMed-indexed studies on DNA methylation panels, while later clinical evaluations highlighted its diagnostic and prognostic relevance, including noninvasive CRC detection studies and epigenetic silencing analyses. The most recent work continues this trajectory, as shown in a 2024 PubMed study on SFRP2 epigenetic silencing in CRC.

Primary transcriptomic and epigenomic datasets involving SFRP2 are publicly available through the NCBI Gene Expression Omnibus (GEO), enabling independent reanalysis and cross-study validation. Such resources are essential for reproducibility and mechanistic refinement.

SFRP2 is not a binary Wnt antagonist or agonist, nor is it confined to a single disease category. Instead, it functions as a microenvironment-sensitive extracellular signaling regulator, whose biological effects depend on cell type, receptor context, ligand availability, and pathological state. This complexity explains its sustained presence in high-impact studies across angiogenesis, fibrosis, cancer biology, and translational biomarker research.